We evaluated the effect of morphine on human dendritic cells (DCs). Interestingly, immature DCs were found to express all 3 (μ, κ, δ) opioid receptors on the cell surface. Chronic morphine treatment (10 -8 to 10 -12 M) during the development of DCs from monocytes augmented LPS-induced upregulation of HLA-DR, CD86, CD80, and CD83 and increased the T cell stimulatory capacity of DCs, which could be inhibited by naloxone, an opioid receptor antagonist. The change in surface phenotype was paralleled by a p38 MAPK-dependent decrease in IL-10 and increase in IL-12 secretion. Our data indicate that morphine exerts an immunostimulatory effect by modulating LPS-induced DC maturation.
INTRODUCTION
The observation that individuals under severe stress or addicted to opioids are generally immunosuppressed (1-3) has led to the notion of a neuroendocrine-immune network. Neuroactive ligands exert a powerful effect on cells of the immune system. There is growing evidence that opioid receptors are expressed by cells of the immune system and that opioids modulate immune responses. In contrast to endogenous opiates that exert immunostimulatory effects (3, 4) , both the therapeutic and chronic use of morphine compromise the optimal function of the immune system (5) . Opiate addicts are prone to infection. This effect of opiates has been attributed to a variety of its immunomodulatory effects (6) . Chronic administration of morphine affects both innate and adaptive immunity (7) .
Morphine given in vivo suppresses a variety of immune responses, including rat T and natural killer (NK) cells (8) , macrophages, rat and macaque polymorphonuclear leukocytes (PMNs) (9, 10) , and lymphocyte circulation in macaques (11) . Morphine-receiving mice have splenic and thymic atrophy (12) , morphine triggers T cell apoptosis in in vitro studies (13) , and enhances macrophage apoptosis in murine macrophages (14) . Several reports address the role of macrophages in morphine-induced modulation of immunity (15) (16) (17) (18) (19) (20) . These studies pertain to a variety of macrophage functions including phagocytosis, tumoricidal activity, generation of nitric oxide and reactive oxygen species, and cytokine synthesis. Undoubtedly, these studies have significantly advanced our understanding of the role of opiates in the modulation of immunity; nevertheless, the effect of morphine on immunity still remains a complex puzzle.
Dendritic cells (DCs) play a central role in the initiation and control of an adaptive immune response (21) . Dendritic cells link the innate to the adaptive immune response by their ability to detect and capture foreign antigens and efficiency to present antigens to T cells. Following the uptake and processing of antigens in the periphery, immature DCs migrate to the T cell-rich areas of lymphoid organs and undergo a maturation process. Mature DCs are potent stimulators of primary T cell and memory responses; they also produce an array of cytokines and chemokines (21) . Factors that modify the DC maturation process can influence the immune response against pathogens and or vaccines. In addition to pathogen components and inflammatory cytokines, DCs respond to a growing number of neuropeptides; for example, calcitonin gene-related peptide inhibits the antigen-presenting capacity of DCs (22, 23) , substance P enhances nuclear factor kappa B (NF-κB) activation Morphine Reciprocally Regulates IL-10 and IL-12 Production by Monocyte-Derived Human Dendritic Cells and Enhances T Cell Activation (24) , and the vasoactive intestinal peptide synergizes with TNF-α to increase IL-12 production and enhance DC maturation (25) . Murine DCs have been shown to express functional κ-opioid (26) as well as δ-and μ-opioid (27) receptors. Stimulation with the κ agonist dynorphin suppressed the T cell stimulatory capacity of DCs without affecting antigen uptake or phenotypic maturation (26) . Expression of δ-opioid receptor has also been detected on human DCs (27) .
We sought to investigate the consequence of morphine on the differentiation process of human myeloid DCs from monocytes. Our data show that exposure of monocytes to morphine during the differentiation process into DCs enhances the T cell stimulatory capacity of lipopolysaccharide (LPS)-matured DCs, which is mediated through classic opioid receptors. This is paralleled by a p38 MAPK-dependent increase in IL-12 p70 secretion and decrease in IL-10 production. In contrast to studies in T cells and some reports on macrophages, morphine enhances the response of DCs to a stimulus and exerts an immunomodulatory function that is likely to amplify a Th1 immune response. Thus, human monocytes and DCs can be participants in the neuroimmune dialog.
MATERIALS AND METHODS

Reagents
The p38 MAPK-specific inhibitor, SB203580, a pyridinyl imidazole compound, the MEK inhibitor PD98059, and N-tosyl-L-phenylalanine chloromethyl ketone (TPCK) were purchased from Sigma (St. Louis, MO, USA). The inhibitors were used at a final concentration of 5 μM. These reagents were solubilized in DMSO; therefore, DMSO, in identical concentrations, was also used in controls. Dr. Singhal obtained morphine from the National Institute for Drug Abuse.
Isolation and Generation of DCs
DCs were generated from peripheral blood mononuclear cells (PBMCs 
Measurement of Cytokines and Chemokines
Cell culture supernatants were collected from day-9 DCs. Cells were left untouched after the initial seeding. The production of cytokines and chemokines in DC supernatants was measured by ELISA (Pierce Boston Technology Center, SearchLight Proteome Arrays Multiplex Sample Testing Services, Woburn, MA, US) 48 h after activation with LPS at day 7.
T Cell Isolation
T cells were isolated by negative selection using the RosetteSep antibody cocktail from Stem Cell Technologies (Vancouver, Canada) according to the manufacturer's instructions. The isolated T cells were routinely ~99% pure.
Mixed Leukocyte Reaction
To assess levels of cellular activation and proliferation, cells were plated at 
RESULTS
Morphine Modifies LPS-Induced DC Maturation
The effects of opioids are mediated by at least 3 different opioid receptors termed μ, κ, and δ, which belong to the G-protein coupled membrane receptor family (28) . The expression of morphine receptors on the cell surface of CD14 + monocytes was investigated by flow cytometry. Monocytes were found to express all 3 opioid receptors ( Figure 1A,B) . Immature DCs and LPS-matured DCs expressed similar levels of all 3 opioid receptors, and the expression did not differ significantly from that of monocytes ( Figure 1B ). Chronic morphine stimulation was mimicked by adding morphine to the monocyte cultures at days 1, 3, and 5 during the differentiation process. The presence of morphine during the development of DCs from monocytes did not significantly alter the cell surface phenotype of immature DCs (data not shown). When immature DCs that had been cultured in the presence of morphine were stimulated with LPS, however, morphine-treated DCs showed increased expression levels of HLA-DR, CD86, and CD83 compared with DCs differentiated in the absence of morphine (Figure 2) . No changes were observed in the expression levels of CD80, CD40, and CD54 (data not shown). The doses tested were physiological (< 10 ). No difference in morphology was observed between morphine-exposed and nonexposed DCs, and the yield of DCs was not affected by morphine (data not shown).
Another characteristic of mature DCs is the secretion of cytokines. To analyze whether morphine treatment altered the cytokine profile of LPS-matured DCs, cell culture supernatants were analyzed for IL-10 and IL-12. Morphine consistently reduced LPS-induced IL-10 secretion almost completely (to the levels present in immature DCs) in all 6 donors tested and increased LPS-induced IL-12 (p70) production in 4 of 6 donors tested (Figure 3) . Furthermore, morphine did not induce changes in the cytokine profile in immature DCs (data not shown).
Morphine Mediates Changes in IL-12 Secretion through p38 MAPK
To investigate the involvement of MEK, p38 MAPK, PI3K, and NF-κB pathways in morphine-mediated changes of IL-12 and IL-10 production, we used their specific inhibitors, PD98059, SB203580, LY294002, and TPCK, respectively (Figure 4A) . The LPS-induced secretion of IL-10 was completely reduced by the p38 MAPK inhibitor SB203580 ( Figure 4A,B) . Morphine-mediated reduction of IL-10 secretion in LPS-matured DCs could not be reversed by any of the other inhibitors tested ( Figure 4A ). The LPS-induced IL 12 secretion and the morphine-mediated increase in IL-12 production were both reduced using the p38 MAPK inhibitor (Figure 4A,B) . None of the other inhibitors reduced the morphine-augmented IL-12 levels ( Figure 4A ).
Morphine Enhances the T Cell Stimulatory Capacity of LPS-Matured DCs
Mature, cytokine-producing DCs induce T cell activation and proliferation, leading to the development of adaptive immunity (21). Because we found that morphine reduces IL-10 production in LPS-matured DCs, and because IL-10 is known to reduce T cell proliferation (29), we tested whether morphine-treated mature DCs would show an increased T cell stimulatory capacity. Immature DCs were generated in the presence or absence of morphine for 7 days and matured by exposure to LPS for 48 h. DCs were harvested and cocultured with allogeneic T cells for 5 days. Morphinetreated LPS-matured DCs showed increased activation of T cells ( Figure 5A ). To further evaluate whether morphine exerts its effect on DCs though opioid receptors, immature DCs were generated in the presence or absence of morphine as described above. The morphinetreated group was divided into two groups: one received only morphine every other day of culture and the other was exposed to the opioid antagonist naloxone on alternating days of morphine treatment. We found that the increased T cell stimulatory capacity of morphine-treated mature DCs could be blocked by naloxone ( Figure 5B ).
DISCUSSION
Morphine is widely used in the clinic. When given in vivo, morphine suppresses a variety of immune responses, including rat T and NK cells (8) , macrophages, rat and macaque PMNs (9, 10) , and lymphocyte circulation in macaques (11) . Although some studies have recently been performed in mouse DCs, the function of opioid receptors on human DCs has not been investigated. We show that human monocytes express all 3 opioid receptors on the cell surface and that chronic exposure of monocytes to morphine during the DC differentiation process enhances the T cell stimulatory capacity of LPS-matured DCs. It has been shown that mouse DCs that were cultured with the κ-opioid-specific antagonist dynorphin overnight showed suppressed T cell activation, but their phenotypic maturation was not affected (26) . The mouse spleen contains several subtypes (plasmacytoid and myeloid) of DCs that are CD11c + , each of which could respond in a different way to dynorphin. Therefore, mouse splenic CD11c + cells cannot be directly compared with our human myeloid DCs. Also, in our system, we are chronically exposing monocytes to morphine during the differentiation processes into DCs. Our experiments were designed to mimic constant exposure of differentiating DCs to morphine, which would be the case in people chronically exposed to morphine. Morphine was added to the cultures until day 5, and potential leftover morphine was not removed when the DCs were exposed to LPS. We do not know how a one-time exposure of immature DCs to morphine would affect their response to LPS. Morphine stability and turnover of opioid receptors bound to morphine on DCs remains to be tested. Also, it still needs to be evaluated whether morphine acts specifically on stimuli that go through tolllike receptors, such as LPS, and whether the same effects will be observed with other DC maturation stimuli such as CD40L.
Here we show that morphine exerts stimulatory effects on human myeloid DCs in vitro. The different results obtained in comparison with the mouse DCs could be because morphine can signal through all 3 opioid receptors, whereas dynorphin is κ-receptor specific. Furthermore, it is likely that a mixture of myeloid and plasmacytoid DCs responds differently than a culture of only myeloid DCs, as in our experiments. Another study showed that mouse bone marrow-derived DCs show increased T cell activation when incubated with δ-or μ-specific agonist (30) . These bone marrow-derived DCs were generated in the presence of GM-CSF, which yields only myeloid DCs (31) . Therefore, this system resembles our human in vitro culture system, and the results obtained with regard to T cell activation are in concordance. A DC-stimulatory property of another neuroactive ligand has recently been identified. Basu and Srivastava (32) showed that DCs express the vanilloid receptor 1, which binds capsaicin and acts on neurons to convey the sensation of pain. Engagement of the vanilloid receptor with capsaicin caused maturation of DCs. Thus, it appears that the signals for pain and immunomodulation are intricately linked. Our results show that prolonged exposure of DCs to morphine during their differentiation from monocytes leads to a MAPK-dependent increase in IL-12 production when stimulated with LPS. This was paralleled by an increased T cell stimulatory capacity that could be blocked using the opioid antagonist naloxone, suggesting involvement of a classic opioid receptor.
IL-10 can inhibit LPS-induced DC maturation (33, 34) . It also functions as an endogenous inhibitor of IL-12 in DCs (35) and Th1 responses but stimulates Th2 cell population and humoral immunity, whereas IL-12 is an inducer of cellmediated immunity that promotes the development, proliferation, and function of Th1 cells. IL-12 promotes the activation and function of NK cells, T cell cytotoxicity, and production of IL-2 and IFN-γ (36). Because morphine-treated DCs showed enhanced IL-12 production, this effect of morphine may be the result of the morphine-induced inhibition of IL-10 generation. In murine macrophages, morphine increased IL-12 production but did not alter IL-10 production (37). This could be due to species differences or different signaling pathways utilized in macrophages and DCs.
Only the p38 MAPK inhibitor SB203580, and none of the other inhibitors tested, reduced the morphine-augmented IL-12 levels, suggesting that morphine mediates increased IL-12 production via a p38 MAPK-dependent pathway. It is likely that morphine increased the amount of phosphorylated p38 in DCs. However, we cannot exclude that morphine also alters other signaling pathways that were not investigated in this study.
Endogenous opiates exert immunostimulatory effects (3, 4) . Helper T cells produce endogenous opioids, and memory T cells within inflammatory tissue are capable of synthesizing and releasing β-endorphins (38) (39) (40) . Because DCs can respond to exogenous opioids, endogenous opioids might play a role in DC-T cell communication. When released from helper T cells, opioids could act on DCs to foster increased IL-12 production, which would shift the helper T cells to a Th1 phenotype.
Even though morphine has been shown to exert inhibitory effects on T cells and in certain conditions macrophages (6, 14) , our data show that it exerts a stimulatory effect on DCs in vitro. However, in vivo an increased Th1 response due to high levels of IL-12, and increased T cell proliferation in the context of an infection, might not be desirable and have negative effects on the host's immune response. As it has been shown that exaggeration of the IL-12 response may result in endotoxic shock (41, 42) or allograft rejection (41) (42) (43) (44) and can block antiparasitic immunity (45) , the stimulatory effect of morphine on DCs might in fact have a negative impact on the development of an immune response in vivo. On the other hand, ex vivo-generated DCs that are used for immunotherapy of cancer patients, if generated in the presence of morphine, might induce a stronger immune response to tumor because of elevated IL-12 levels.
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We wish to thank Gloria Telusma and Nick Franki for their technical assistance and Cathy Rapelje for FACS analysis. We also thank Ona Bloom for critical reading of the manuscript. This work was supported by grants (5RO1DA 12111) from the National Institutes of Health. days. DCs were exposed to medium only (IM) or LPS (100 ng/mL) for 48 h. LPS, immature DCs exposed to LPS; LPS + morphine, morphine-treated immature DCs exposed to LPS. Two days after exposure to LPS, DCs were cocultured with 10 5 allogeneic T cells at a DC:T cell ratio of 1:100. T cell proliferation was assessed by measuring the amount of [ 3 H]thymidine incorporated during the last 8 h of a 5-day culture period. The results shown are mean ± SEM of 3 independent experiments using DCs generated from different donors. (B) Immature DCs were differentiated in the absence or presence of morphine (10 -8 M) for 7 days. The morphinetreated group was divided into two groups: one received only morphine and the other morphine and naloxone (10 -6 M) on alternating days until day 7. On day 7, DCs were exposed to medium only (IM) or LPS (100 ng/mL) for 48 h. On day 9, DCs were harvested, washed, and cocultured with 10 5 allogeneic T cells at a DC:T cell ratio of 1:100. T cell proliferation was assessed by measuring the amount of [
